QUINTILES ADDS TO GLOBAL BIOSTATISTICS & INTERNATIONAL ECG MONITORING THROUGH ACQUISITIONS IN SOUTH AFRICA AND U.K.

RESEARCH TRIANGLE PARK, N.C. - June 29, 1998 - Quintiles Transnational Corp. (Nasdaq: QTRN) announced today the acquisitions of ClinData International Pty Ltd., South Africa’s leading biostatistics and data management company, and U.K.-based Cardiac Alert, which provides a centralized electrocardiogram (ECG) monitoring service for international clinical trials.

Quintiles acquired ClinData and Cardiac Alert in exchange for Quintiles Transnational stock in separate pooling of interests transactions.Each transaction is expected to be neutral to slightly accretive to Quintiles’ earnings per share.

“These acquisitions reflect our commitment to global expansion and new technologies to speed and improve clinical trials,” said Ludo Reynders, Ph.D., Chief Executive Officer of Quintiles Contract Research Organization (CRO) service group. “ClinData’s outstanding reputation and extensive experience make it an excellent fit with Quintiles. We now have more than 250 employees in South Africa providing the full spectrum of contract research and sales and marketing services.

“Cardiac Alert’s trans-telephonic ECG monitoring service offers dramatically increased speed and higher quality data in both regional and global clinical trials, which is a key component of our TotalAcceleration program for faster and better drug development.”

Led by renowned biostatisticians Herman Luus, Ph.D., and Robert Schall, Ph.D., ClinData provides a complete range of data management and biostatistics services, including medical writing, to international pharmaceutical companies conducting clinical trials in Europe, South Africa and Southeast Asia. The company is based in Bloemfontein, about 250 miles southwest of Johannesburg.

“We’re delighted to join Quintiles in providing biostatistics and data management services to both international and local customers,” said Dr. Luus, ClinData Managing Director. “Quintiles is the leader in clinical research services worldwide and in South Africa, and the addition of ClinData’s data management and biostatistics expertise offers exceptional possibilities for further growth in South Africa and other areas.”

Cardiac Alert is Europe’s leading provider of centralized trans-telephonic ECG monitoring services for international clinical trials. Investigator sites with Cardiac Alert’s ECG monitors transmit real-time ECG signals by telephone to a central evaluation center in London, where cardiologists analyze the data and have the capability to either fax or phone back reports within 30 minutes. More than 600 sites in 26 countries utilize Cardiac Alert’s services to screen prospective patients and monitor patients involved in clinical trials.

“We’re pleased to help Quintiles reach its goal of accelerating clinical trials while maintaining or increasing quality,” said Cardiac Alert Managing Director Mike Parker. “Cardiac Alert’s services reduce the time required for ECG monitoring and help ensure consistency in evaluating ECG data from patients at multiple investigator sites.”

ClinData, which has 27 employees, will do business as Quintiles ClinData. Quintiles Transnational’s operations in South Africa now comprise ClinData, Quintiles Clindepharm (clinical research) and Innovex South Africa (sales and marketing), and more than 250 employees. Quintiles has entered into employment agreements with ClinData senior managers, including Dr. Herman Luus, as Managing Director, and Dr. Robert Schall and Theo Erasmus, as Directors. ClinData will continue to be located at 1 Third Avenue, Westdene 9201, Bloemfontein, South Africa, phone +27 51 447 8477, fax +27 51 447 7981.

Cardiac Alert’s 16 employees will be part of Quintiles CRO service group and continue to operate from their current location at 99 King’s Road, Chelsea, London, SW3 4PA, U.K., phone +44 171 352 8585, fax +44 171 352 2799. Quintiles has entered into employment agreements with Mike Parker, Medical Director Dr. Boaz Mendzelevski and other Cardiac Alert senior managers.

Quintiles Transnational Corp. is the market leader in providing full-service contract research, sales and marketing, healthcare policy consulting and health information management services to the worldwide pharmaceutical, biotechnology, medical device and healthcare industries. Quintiles is headquartered near Research Triangle Park, North Carolina. With 13,000 employees worldwide and offices in 28 countries, Quintiles operates through specialized work groups dedicated to meeting individual customer needs.

Information in this press release contains “forward-looking statements.” These statements involve risks and uncertainties that could cause actual results to differ materially, including without limitation, the ability of the combined businesses to be integrated with Quintiles’ current worldwide operations, actual operating performance, the ability to maintain large client contracts or to enter into new contracts, and the actual costs of combining the businesses. Additional factors that could cause actual results to differ materially are discussed in the company’s recent filings with the Securities and Exchange Commission, including but not limited to its S-3 and S-4 Registration Statements, its Annual Report on Form 10-K, its Form 8-Ks, and its other periodic reports, including Form 10-Q, exhibit 99.01.

Contacts

Greg Connors, Investor Relations
Office: +1 919 998 2000

Pat Grebe, Media Relations
919 998 2091